Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective

The banal value of a brace of pharmaceutical companies are moving successful other directions Tuesday pursuing nan publication of a caller technological study, pinch Eli Lilly (LLY) shares rising and American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) slipping.

On Monday, nan JAMA Internal Medicine aesculapian diary recovered that tirzepatide, nan progressive constituent successful Eli Lilly's Mounajro and Zepbound, is much effective astatine causing weight nonaccomplishment than semaglutide, nan progressive constituent successful Novo Nodrisk's Ozempic and Wegovy.

Study Finds Eli Lilly Drugs Caused More Weight Loss and astatine a Faster Pace

The study analyzed nan weight-loss progression of complete 18,300 patients who receiving semaglutide aliases tirzepatide for type 2 glucosuria betwixt May 2022 done November 2023.

Those taking Eli Lilly's tirzepatide were much apt to suffer from 5% to 15% aliases greater assemblage weight, and were besides much apt to person mislaid much weight astatine 3, 6, and 12 months aft starting treatment.

"Individuals pinch overweight aliases obesity treated pinch tirzepatide were importantly much apt to execute clinically meaningful weight nonaccomplishment and larger reductions successful assemblage weight compared pinch those treated pinch semaglutide," nan authors wrote, besides noting that early studies should beryllium conducted to way really effective nan narcotics are astatine preventing different wellness risks for illustration bosom attacks.

Eli Lilly, Novo Nordisk Sales, Share Prices Have Been Soaring

Thanks to nan fame of their weight-loss drugs, Eli Lilly and Novo Nordisk person seen gross and profits emergence substantially successful nan past respective quarters, and person worked to summation accumulation capacity to meet precocious demand.

In its astir caller net study successful May, Novo Nordisk said Ozempic and Wegovy income roseate 25% year-over-year, while Eli Lilly said income of Mounjaro much than tripled to $1.81 cardinal and Zepbound income had grown to $517.4 cardinal aft only launching successful November 2023.

ADRs of Novo Nordisk were down 1.5% to $140.94 by astir 1 p.m. ET Tuesday, while Eli Lilly shares were up 0.8% to $925.18. Novo Nordisk banal is up complete 35% truthful acold this year, while Eli Lilly is up astir 60%.

Investopedia requires writers to usage superior sources to support their work. These see achromatic papers, authorities data, original reporting, and interviews pinch manufacture experts. We besides reference original investigation from different reputable publishers wherever appropriate. You tin study much astir nan standards we travel successful producing accurate, unbiased contented successful our editorial policy.